A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
Status:
Completed
Trial end date:
2019-03-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the effect of selpercatinib on how fast
repaglinide gets into the blood stream and how long it takes the body to remove it when
administered in healthy participants. Information about safety and tolerability will be
collected. The study will last up to 12 days.